Royalty Report: Drugs, Wound Care, Medical – Collection: 6107

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • Wound Care
  • Medical
  • Supply
  • Biotechnology
  • Therapeutic
  • cardiac
  • Vaccine

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 6107

License Grant
Licensor hereby grants to Licensee a non-revocable, royalty-bearing exclusive right within the Territory to the Patent Rights in the Field, including the right to sublicense to third parties within the Field, provided that any third party sublicensee shall be subject to all of Licensee's obligations.
License Property
The Parties entered into a joint patent ownership and License Agreement dated as of August 16, 2004, which was later amended and restated as of May 23, 2006, for consideration the sufficiency of which was acknowledged in each Agreement, pursuant to which Licensor granted Licensee a 50% ownership interest in certain patents and patents applications listed in the Joint Ownership Agreement, as well as certain future patent rights, and the parties acknowledge that Licensee would have exclusive rights within a defined filed, while Licensor would have exclusive rights outside that field. Licensee and Licensor now wish to enter a new Agreement superseding the Joint Ownership Agreement so as to specify those future patents and patent applications that are to be subject to joint ownership and so as to restate the Licenses granted in the Joint Ownership Agreement. The Parties acknowledge that the jointly owned and cross-Licensed rights are vital to the parties’ respective plans for development and commercialization and wish to further clarify the parties’ respective rights and provide for continued access to the necessary rights in the event of insolvency.

Jointly Owned Patent Applications shall mean the pending Foreign Patent Applications listed below, including any foreign national patent applications which claim priority to the Foreign Patent Applications and any Future Patent Applications, including any continuations, divisionals, re-exams, reissues and continuations-in-part and any other forms of related applications, that claim domestic or international priority to any of the Issued United States or foreign patents, or pending international or foreign patent applications, specifically listed by patent or application number herein.

(a) Issued US Patents

(i) U.S. 6,268,178 entitled Licensor-Dependent Super-Production of Biologically Active Protein and Peptides; and

(ii) U.S. 6,642,026 entitled Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis.

(iii) U.S. 6,773,899 entitled Licensor-Dependent Super-Production of Biologically Active Protein and Peptides;

(iv) U.S. 6,794,162, entitled Licensor-Dependent Super-Production of Biologically Active Protein and Peptides;

(b) Foreign Patent Applications

(i) International Patent Applications. All foreign patent applications related to the above-referenced U.S. patents and applications and claiming priority to the following international patent applications under the Patent Cooperation Treaty (PCT)

A. International Patent Application No. PCT/US00/40020, published as International Publication No. WO 00/71731 A2 on November 30, 2000 entitled Licensor-Dependent Super-Production of Biologically Active Protein and Peptides.

Field of Use
The Licensee plans to develop and commercialize therapeutic methods related to the induction of angiogenesis or wound healing by administration of Fibroblast Growth Factor (FGF); and, the Licensor plans to develop and commercialize recombinant DNA methods for producing peptides/proteins.

Field shall encompass any angiogenic or wound healing compositions, (including in particular, but without limitation, all FGF species, fragments, derivatives, and analogs thereof, nucleic acid sequences encoding angiogenic or wound healing proteins/peptides), vectors and host cells comprising said DNA sequences, methods of making the angiogenic or wound healing compositions, and methods of inducing angiogenesis or wound healing employing the said compositions. CARDIO-developed devices and methods of use thereof for delivery of angiogenic or wound healing compositions are not included within the Field, and are not subject to joint ownership or any other terms of this Agreement.

IPSCIO Record ID: 4236

License Grant
The Parties wish to jointly own all patents related to Fibroblast Growth Factor and the methods for producing and using FGF, whether such patents are developed jointly or individually by either party; and wish to License from one another exclusive rights to practice under the jointly owned patents in accordance with their respective plans for development and commercialization.

Licensor hereby agrees to assign to the Licensee a 50% ownership interest in the itemized patents and patent applications.

License Property
The Licensee will have a non-revocable, royalty-bearing, exclusive right within the territory to the Patent Rights in the Field, including the right to subLicense to third parties within the Field.

The Licensor will have a non-revocable, royalty free, exclusive right within the territory to the Patent Rights in all other fields outside of the Field, including the right to subLicense to third parties outside of the Field, encompassing any angiogenic or wound healing compositions, (including in particular, but without limitation, all FGF species, fragments, derivatives, and analogs thereof, nucleic acid sequences encoding angiogenic or wound healing proteins/peptides), vectors and host cells comprising said DNA sequences, methods of making the angiogenic or wound healing compositions, and methods of inducing angiogenesis or wound healing employing the said compositions.

1. U.S. 6,268,178 entitled Phage-Dependent Super-Production of Biologically Active Protein and Peptides.
2. U.S. 6,642,026 entitled Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis.
3. U.S. 6,773,899 entitled Phage-Dependent Super-Production of Biologically Active Protein and Peptides.
4. U.S. 6,794,162, entitled Phage-Dependent Super-Production of Biologically Active Protein and Peptides.
Pending US Patent Applications 1.. U.S. 10/649,480 entitled Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis; published as US Patent Application No. US 2004/0115769 .

1. International Patent Application No. PCT/US00/40020, published as International Publication No. WO 00/71731 A2 on November 30, 2000 entitled Phage-Dependent Super-Production of Biologically Active Protein and Peptides.
2. International Patent Application No. PCT/US01/25537, published as International Publication No. WO 02/14471 A2 on February 21, 2002 entitled Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis.
3. International Patent Application No. PCT/US01/25477, published as International Publication No. WO 02/14468 A2 on February 21, 2002, entitled Phage-Dependent Super-Production of Biologically Active Protein and Peptides.

Field of Use
Field shall encompass any angiogenic or wound healing compositions, (including in particular, but without limitation, all FGF species, fragments, derivatives, and analogs thereof, nucleic acid sequences encoding angiogenic or wound healing proteins/peptides), vectors and host cells comprising said DNA sequences, methods of making the angiogenic or wound healing compositions, and methods of inducing angiogenesis or wound healing employing the said compositions.

IPSCIO Record ID: 5858

License Grant
The Licensor has granted the Licensee a non-revocable and exclusive worldwide license including the right to sublicense to third parties to the patents necessary to develop and commercialize drug candidates in which Cardio Vascu-Grow is the active ingredient. As a part of that agreement, Licensor will provide technical development services to us for the development and regulatory approvals of our drug candidates, including but not limited to, lab work, testing and production of our drug candidates in which Cardio Vascu-Grow is the active ingredient for clinical trials, all as directed by us.
License Property
We are working closely with an affiliated company, Cardio, pursuant to a joint patent and technology sharing agreement, to manufacture human fibroblast growth factor-1 (Cardio Vascu-Grow) for Cardio’s ongoing clinical trials.

Cardio Vascu-Grow Human Fibroblast Growth Factor-1 treat patients with advanced atherosclerotic disease of their coronary arteries. This treatment, which regenerates new blood vessels in the hearts of these patients.  Atherosclerosis is a disease affecting arterial blood vessels. It is a chronic inflammatory response in the walls of arteries, in large part due to the accumulation of macrophage white blood cells and promoted by low density (especially small particle) lipoproteins (plasma proteins that carry cholesterol and triglycerides) without adequate removal of fats and cholesterol from the macrophages by functional high density lipoproteins (HDL), (see apoA-1 Milano).

Issued US Patents
1. U.S. 6,268,178 entitled “Phage-Dependent Super-Production of Biologically Active Protein and Peptides;” and
2. U.S. 6,642,026 entitled “Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis.”
3. U.S. 6,773,899 entitled “Phage-Dependent Super-Production of Biologically Active Protein and Peptides”;
4. U.S. 6,794,162, entitled “Phage-Dependent Super-Production of Biologically Active Protein and Peptides;”
Pending US Patent Applications 1.. U.S. 10/649,480 entitled “Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis;” published as US Patent Application No. US 2004/0115769

Field of Use
Cardio Vascu-Grow™ stimulates the growth of new blood vessels, a biological process termed “angiogenesis”. This growth factor is being tested in a wide variety of human diseases that would benefit from increased angiogenesis including coronary artery disease, stroke, and peripheral vascular disease of the legs and wound healing.

IPSCIO Record ID: 5907

License Grant
The Company entered into an Agreement, which has been superseded by a new exclusive License Agreement dated February 20, 2007, with Korean Company (Licensee) to commercialize its future products. The Company transferred to Licensee the rights to market its products for 99 years in all of the Republic of Korea, China, and Taiwan.
License Property
The Company did this by exclusively licensing its patents to Licensee in Korea, China and Taiwan in the field of any angiogenic or wound healing compositions and methods of use for which the Company has received marketing approval in the United States, Europe or Japan (including in particular, but without limitation, all FGF species, fragments, derivatives, and analogs thereof), and methods of making the approved angiogenic or wound healing compositions, including any nucleic acid sequences encoding said compositions and any vectors and/or host cells comprising said nucleic acid sequences.
Field of Use
In the field of any angiogenic or wound healing compositions.

IPSCIO Record ID: 372627

License Grant
By the 2003 agreement, Licensor granted an exclusive worldwide sublicense for the Licensed Technology in the Field of Use and the Field of Extended Use.  This amended and restated agreement is to continue the Exclusive Sublicense with the amendments.

Licensor grants an exclusive worldwide license under the Licensed Technology to use, offer to sell, sell, and otherwise commercialize, solely in the Field of Use and the Field of Extended Use, Licensed Products which include rhPDGF-BB purchased from Licensor.

For the Sublicenses, Licensor grants the right to grant sublicenses under the Licensed Technology to Distributors to use, offer to sell and sell, in the Field of Use and the Field of Extended Use, Licensed Products purchased from Licensor.

License Property
Licensed Products means any product consisting essentially of rhPDGF-BB in the absence of other growth-promoting proteins and in combination with a synthetic or natural matrix, or any part thereof i.e., any product consisting essentially of rhPDGF-BB in the absence of other growth-promoting proteins without a matrix, or a synthetic or natural matrix alone, that is covered by the Licensed Patents; is developed through the use of a process that is covered by the Licensed Patents or could not be manufactured, used or sold without the incorporation or use in whole or in part of some or all of the Licensed Patents.

Proven rhPDGF technology is FDA approval of GEM 21S for periodontal bone regeneration suggests potential for efficacy in other bone and musculoskeletal applications.

Field of Use
GEM 21S was approved by the U.S. Food and Drug Administration the treatment of periodontal bone defects and gum tissue recession associated with periodontal disease.

GEM 21S® growth-factor enhanced matrix is indicated to treat the following periodontally related defects intrabony periodontal defects; furcation periodontal defects; and gingival recession associated with periodontal defects.

GEM 21S® growth-factor enhanced matrix combines a bioactive protein – highly purified rhPDGF-BB – with an osteoconductive matrix, ß-TCP.

GEM 21S® is the only dental therapy containing rhPDGF-BB, one of the main growth factors found in the human body and well known for its stimulatory role in wound healing.

This completely synthetic grafting system is engineered to stimulate wound healing and bone regeneration when implanted in the body by triggering a cascade of molecular events that continues on even after the implanted rhPDGF-BB is gone.

The Field of Use means all uses related to the treatment, cure, or relief of mammals for periodontal diseases and/or the repair, restoration or reconstruction of oral and cranio• maxillofacial osseous defects.

The Field of Extended Use shall mean all uses outside the Field of Use that are related to the treatment and healing of bone, cartilage, tendon and ligaments of the skeletal tissue system in animals, excluding humans, excluding the treatment and healing of soft tissue wounds.

IPSCIO Record ID: 239011

License Grant
Licensor hereby grants to Licensee a worldwide, exclusive (even as to Licensor), royalty-bearing license in the Field, including the right to grant sublicenses, under the Licensor Patent Rights, the Licensor ownership interest in Joint Patent Rights, Licensor Know-How and Licensor Inventions to make, have made, have used, sell, have sold, offer for sale, and import Licensed Products in the Field. Licensee shall not make, use, sell market or promote Licensed Product for use outside the Field. Where the Licensor Patent Rights are themselves licensed from a Third Party, Licensors license shall take the form of a sublicense.
License Property
Licensor Patent Rights shall mean

(a) the patent and patent applications listed, which shall be updated by Licensor as appropriate from time to time, all patent applications heretofore or hereafter filed or having legal force in any country owned by or licensed to Licensor or to which Licensor otherwise acquires rights, which claim a composition, method or process for biologics or technology, including, but not limited to, cells, cell lines, genes, peptides and proteins which are necessary or useful to practice any process or method related to, or to make, use or sell any Licensed Product in the Field, including Inventions, together with any and all patents that have issued or in the future issue therefrom, including utility, model and design patents and certificates of invention, and

(b) all divisionals, continuations, continuations-in-part, continued prosecution applications, requests for continued examination, reissues, renewals, extensions or additions to any such patents and patent applications; all of Section (a) and this Section (b) of this paragraph to the extent and only to the extent that Licensor hereafter will have the right to grant licenses, immunities or other rights thereunder, and any foreign counterparts to those patents and patent applications, and currently consisting of the Licensor Patent Rights described hereto.

(c) Patents and patent applications licensed to Licensor by a Third party or to which Licensor otherwise acquires rights after the effective date of this Agreement shall become part of the Licensor Patent Rights to the extent that Licensor has the right to grant licenses to Licensee in the Field and only to the extent that Licensor is able to do so on economic terms substantially similar to the economic terms of its primary licenses from third parties as of the effective date.

Licensee Patent Rights
1. 'Polypeptides and Polynucleotides From Coagulase-Negative Staphylococci'
U.S. provisional application 60/098,443 filed 8-31-98 and refiled to add additional subject matter as 60/117,119 on 1-25-99. These provisional applications were converted to U.S. application 09/386,962 filed August 31, 1999, and filed as PCT/US99/19728.  (Licensed exclusively to Licensor by The Texas A&M University System (TAMUS) and BioResearch Ireland (BRI). TAMUS and BRI reserve the right to use this technology for noncommercial research and educational purposes. The U.S. Government holds certain rights under 37 CFR 410.14. No license is granted under any service mark or trademark of TAMUS. The name of TAMUS may not be used by Licensee except to state that it is a sublicensee of TAMUS).

2. 'Multicomponent Vaccines'
U.S. provisional Application 60/098,439 filed 8-31-98. This was converted to U.S. application 09/386,959 and PCT/US99/19727 on August  31, 1999. (Licensed exclusively to Licensee by The Texas A&M University System (TAMUS) and Bioresearch Ireland (BRI). TAMUS and BRI reserve the right to use this technology for noncommercial research and educational purposes. The U.S. Government holds certain rights under 37 CFR 410.14.  No license is granted under any service mark or trademark of TAMUS. The name of TAMUS may not be used by Licensee except to state that it is a sublicensee of TAMUS).

3. 'Fibrinogen Binding Proteins From Staphylococcus aureus'
U.S. provisional application filed 11-26-97 as 60/066,815 abandoned in favor of 'Extracellular Matrix-Binding Proteins From Staphylococcus aureus to add additional information, filed 8-31-98 as 60/098,427 converted 11-25-98 to 09/200,650. PCT /US98/25246 was filed 11-25-98.  (Licensed exclusively to Licensee by The Texas A&M University System (TAMUS) and BioResearch Ireland (BRI). TAMUS and BRI reserve the right to use this technology for noncommercial research and educational purposes. The U.S. Government holds certain rights under 37 CFR 410.14. No license is granted under any service mark or trademark of TAMUS. The name of TAMUS may not be used by Licensee except to state that it is a sublicensee of TAMUS).

4. 'Fibronectin Binding Protein Compositions and Methods of Use'
U.S. provisional application filed 1-21-97 as 60/036,139, converted 1-21-98 to 09/010,317; PCT filed 1-21-98 as PCT/US98/01222. (Licensed  exclusively from TAMUS through the AM Fund I to Licensor. TAMUS reserves the right to use this technology for noncommercial research and education purposes. . The U.S. Government holds certain rights under 37 CFR 410.14. No license is granted under any service mark or trademark of TAMUS. The name of TAMUS may not be used by Licensee except to state that it is a sublicensee of TAMUS.)

5. 'Collagen Binding Protein Compositions and Methods of Use'
U.S. provisional application 60/017,678 filed 5-16-96 converted 5-14-97 to 08/856,253; PCT/US97/08210 filed 5-14-97. (Licensed exclusively from TAMUS through the AM Fund I to Licensor. TAMUS reserves the right to use this technology for noncommercial research and education purposes. The U.S. Government holds certain rights under 37 CFR 410.14. No license is granted under any service mark or trademark of TAMUS. The name of TAMUS may not be used by Licensee except to state that it is a sublicensee of TAMUS.)

6. 'S. aureus Fibrinogen Binding Protein Gene'
U.S. application 08/293,728 filed 8-22-94, issued as U.S. patent 6,008,341 on 12-28-99; Div. App. 09/421,868 was filed 10-19-99 and another divisional application was filed 10-5-00. (Licensed exclusively to Licensor by BRI. BRI reserves the right to use this technology for noncommercial research and educational purposes.)

7. 'MHC II Analog From Staphylococcus aureus'
U.S. application filed 5-24-94 as 08/248,021 and issued 7-15-1997 as U.S. patent 5,648,240. (Licensed exclusively from TAMUS through the AM Fund I to Licensor. TAMUS reserves the right to use this technology for noncommercial research and education purposes. The U.S. Government holds certain rights under 37 CFR 410.14. No license is granted under any service mark or trademark of TAMUS. The name of TAMUS may not be used by Licensee except to state that it is a sublicensee of TAMUS.)

8. 'Fibronectin Binding Peptide'
Filings SE 90 2617 filed 8-10-90; U.S. 846,995 filed 6-8-92 now abandoned; U.S. 55,783 filed 5-3-93 now abandoned, U.S. 234,622 filed 4-28-94 issued as U.S. patent 5,440,014 on 8-8-95. (Nonexclusively from Magnus Hook.)

9. 'Fibronectin Binding Protein As Well As Its Preparation'
Filings SE 89 1687 filed 5-11-89; U.S. 520,808 parent filed 5-9-90 issued as U.S. patent 5,175,096 on 12-29-92; U.S. divisional 974,181 filed 11-10-92 now abandoned; U.S. continuation 340,458 filed 11-14-94 issued as U.S. patent 5,652,217, 'Fibronectin Binding Protein' on 7-29-97; U.S. divisional 725,492 filed on 10-4-96 issued as U.S. patent 5,840,846, 'Fibronectin Binding Protein As Well As Its Preparation' on 11-24-98. (Nonexclusively from Magnus Hook.)

10. 'Fibronectin Binding Protein As Well As Its Preparation'
Filings SE 87 2272 filed 6-1-87; U.S. parent 201,028 filed 6-1-88 now abandoned; U.S. continuation 746,087 filed 8-12-91 now abandoned; U.S. continuation 937,817 filed 1-22-93 issued as U.S. patent 5,320,951 on 6-14-94; U.S. divisional 259,000 filed 6-13-94 issued as U.S. patent 5,571,514 'Fibronectin Binding Protein As Well As Its Preparation' on 11-5-96; U.S. divisional 729,767 filed 10-7-96 issued as U.S. patent 5,770,702 'Fibronectin Binding Protein As Well As Its Preparation' on 6-23-98. (Nonexclusively from Magnus Hook.)

11. 'Collagen Binding Protein As Well As Its Preparation'
U.S. application 861,804 filed 8-21-92 now abandoned; U.S. continuation 447,031 filed 5-22-95 issued as U.S. patent 5,851,794 on 12-22 98. (Nonexclusively from Magnus Hook.)

12. 'Method for Prophylactic Treatment of the Colonization of a S. aureus Bacterial Strain By Cell Surface Protein With Fibronectin and Fibrinogen Binding Ability'
Filings SE 8402938 filed 5-30-84; U.S. parent 840,580 filed 1-21-86, now abandoned; U.S. continuation 801,593 filed 12-5-91 and issued as U.S. Patent 5,189,015 on 2-23-93. (Nonexclusively from Magnus Hook.)

13. 'Bacterial Cell surface Protein with Fibronectin, Fibrinogen, Collagen and Laminin Binding Ability, Process for the Manufacture of the Protein and Prophylactic Treatment'
Filings U.S. 06/840,580 filed as PCT/SE85/00227 on 5-30-85; U.S. continuation 07/801,593 filed 12-5-91, now U.S. Patent 5,189,015; U.S. divisional 07/977,151 filed 11-16-92; U.S. continuation 08/118,697 filed 9-10-93 and issued as U.S. Patent 5,980,908 on 11-9-99. (Nonexclusively from Magnus Hook.)

Licensed Product shall mean active human vaccines containing MSCRAMM(TM) proteins derived from S. aureus or S. epidermidis, within the Field the manufacture, use or sale of which, but for the license granted herein, would infringe at least one Valid Claim of Licensor Patent Rights, or utilize Licensor Know-How.

Field of Use
Field shall mean human vaccines for containing MSCRAMM(TM) proteins derived from S. aureus and S. epidermidis for the prevention of S. aureus and S. epidermidis infections, provided, however that the Field shall exclude the use of MSCRAMM(TM) proteins or such vaccines to stimulate antibody titer in plasma donors whose plasma is collected for the purpose of developing and commercializing products containing plasma derived immunoglobulin.

IPSCIO Record ID: 26656

License Grant
A U.S. pharma has granted the worldwide rights to a U.S business unit of an Italian company the Knighton patent for all applications relating to the use of autologous platelet releasate therapies for healing purposes (wound-healing and tissue repair therapies).  U.S. Patent No. 5,165,938 entitled Wound Healing Agents.
License Property
5,165,938 A process for treating a wound of a live animal which comprises applying over the wound an effective amount of a treating composition containing the materials released by platelets during the platelet release reaction and facilitating healing of the wound.
Field of Use
Licensed Fields means any and all fields of use.

IPSCIO Record ID: 5492

License Grant
LICENSOR hereby grants to LICENSEE, to the extent of the LICENSED FIELD and LICENSED TERRITORY, a license under PATENTS, to fully practice PATENTS, including the right to make, use, offer for sale, sell and import PRODUCTS and promote the methods and compositions recited in the claims of PATENTS using PRODUCTS in the LICENSED FIELD.
License Property
The U.S. and foreign issued patents relates to platelet-based growth factors (used in platelet rich plasma gel used in wound care in the specific field of use covering diagnostic and therapeutic spinal, neurosurgery and orthopedic surgery. U.S. Patent No. 5,165,938 entitled “Wound Healing Agents,” issued 11/24/92.
Field of Use
SCHEDULE OF PRODUCTS
SEPARATORS
2760-40-101       Disposable Processing Kit – Single
2760-40-102       Disposable Processing Kit – Double

Disposable Processing Kits contain the items required for containing blood during processing in the centrifuge

CAPITAL
2760-40-000       Centrifuge
2760-40-310       Centrifuge and Cart Assembly

APPLICATORS/ MIXERS
2760-40-200       Applicator Kit

IPSCIO Record ID: 227278

License Grant
University hereby grants to Licensee in the territory and in the field an exclusive commercial license under University patent rights, to make and have made, to use and have used, to sell and have sold the licensed products, and to practice the licensed processes, for the life of the university patent rights. Such licenses shall include the right to grant sublicenses.
License Property
Universitys rights in the United States Patents listed below, and the inventions described and claimed therein
U.S.P.N. 5,019,559 – Wound healing using PDGF and IGF-II
U.S.P.N. 4,861,757 – Wound healing and bone regeneration using PDGF and IGF-I
U .S.P.N. 5,124,316 – Method for periodontal regeneration
U.S.P.N. 4,874,746 – Wound healing composition of TGF-alpha and PDGF
U .S.P .N. 4,983,581 – Wound healing composition of IGF-I and TGF-.beta.
U.S.P.N. 5,256,644 – Wound healing using IGF-II and TGF
U.S.P,N. 5,034,375 – Process of wound healing using PDGF and EGF
U.S.P.N. 5,035,887 – Wound healing composition of IL-1 and PDGF or IGF-1
U.S.P.N. 5,516,699 – Pyridinoline crosslinks as markers of periodontal and peri-implant disease activity

rhPDGF is a bio-active protein that is a key mediator of wound healing and tissue regeneration.

Field of Use
rhPDGF is a key stimulator of the body's natural wound healing process. It has a well-established mechanism of action that leads to stimulation of certain cell types, including those important to bone, cartilage, tendon and ligament healing.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.